The last few years have been significant for the psychedelic therapy industry and we believe the sector is in not even in the first inning of a major growth cycle. From a regulatory standpoint, the psychedelic therapy industry has reported significant advancements, and this is a trend that we expect…
Although 2020 was a banner year for the psychedelic therapy market, we expect 2021 to be an even better year for the sector as leading biotech firms are set to report Phase 3 Food and Drug Administration (FDA) clinical trial data. We have seen the psychedelic sector evolve over the…
ATAI Life Sciences is considered to be a leading player in the psychedelic therapy sector after it closed a $125 million funding round that included a handful of strategic investors. We believe the size of the raise and the types of the investors that were involved with the financing add…
ATAI Life Sciences ( " ATAI" or the " Company") , a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $125 millionSeries C financing round, including $32 million of its 2020 convertible debt that converted in connection with…
2020 has been a banner year for the psychedelic sector and we believe that the industry is in the early stages of a major growth cycle. Last week, Compass Pathways announced a major milestone and filed to go public on the Nasdaq Global Market under the symbol CMPS. The leading…
2020 has been a tough year for global markets and this is a trend that we have been closely following. During the last year, we have seen a rapid increase in the number of companies that are in the psychedelic market and this is a vertical that we have become…
